Two Covid-19 vaccines from Sinopharm Company and Chongqing Tri Phi created immunity against the nCoV variant from South Africa, but was less effective than the original virus.
The results were published on 2/2 in the magazine BioRxiv. Previously, scientists studied 12 samples from people who had received one of the two vaccines from two pharmaceutical companies.
“There is a need for a close look at the inefficiency of the vaccine against the nCoV variant in South Africa, which could affect the clinical efficacy of these two vaccines,” said study authors from the Beijing Institute of Biological Products. Sinopharm Company), Chinese Academy of Sciences, and two other bodies, stressed.
On December 31, 2020, the Covid-19 vaccine developed by Sinopharm became the first “candidate” approved for use by Chinese authorities. Earlier, Sinopharm published preliminary data proving the vaccine is 79% effective, rated as “a breakthrough in the fight against epidemics in Asia”. Sinopharm vaccine is also being used in several countries, including the UAE, Hungary.
Chinese biotechnology companies mainly use traditional technology to develop vaccines. Sinopharm’s “candidate” is based on an inactivated nCoV pattern, which is introduced into the body to teach the immune system how to recognize and kill the pathogen. Products capable of rapid commercialization such as vaccines from American pharmaceutical company Moderna or research group University of Oxford and AstraZeneca.
Chongqing Tri Phi’s Covid-19 vaccine is in phase 3 of clinical trials in China and abroad.
The nCoV variants, including variant 501.V2 from South Africa and variant B.1.1.7 in the UK, are of concern to the health community because of their ability to undermine the effectiveness of vaccines and existing treatments. have. Novavax and Johnson & Johnson pharmacies’ preliminary vaccine clinical trial data also showed that the vaccine’s nCoV prevention was less effective than in volunteers in South Africa, where variant 501.V2 is widely spread.
At the end of January, Pfizer-BioNTech announced its Covid-19 vaccine was effective in preventing nCoV variants from the UK and South Africa. In particular, the company says small differences between the original virus strain and recent variants do not diminish the effectiveness of the vaccine. There is therefore no need to develop a new vaccine to deal with these variants, but will continue to monitor the actual effectiveness of the vaccine, including its ability to fight new variants.
Covid-19 broke out in December 2019, appeared in 219 countries and territories with more than 104 million cases, more than 2.2 million deaths and more than 76 million people recovered.
Le Hang (According to the Reuters)